Nanowell-mediated two-dimensional liquid chromatography enables deep proteome profiling of <1000 mammalian cells

Multidimensional peptide separations can greatly increase the depth of coverage in proteome profiling. However, a major challenge for multidimensional separations is the requirement of large biological samples, often containing milligram amounts of protein. We have developed nanowell-mediated two-di...

Full description

Saved in:
Bibliographic Details
Published inChemical science (Cambridge) Vol. 9; no. 34; pp. 6944 - 6951
Main Authors Dou, Maowei, Zhu, Ying, Liyu, Andrey, Liang, Yiran, Chen, Jing, Piehowski, Paul D, Xu, Kerui, Zhao, Rui, Moore, Ronald J, Atkinson, Mark A, Mathews, Clayton E, Qian, Wei-Jun, Kelly, Ryan T
Format Journal Article
LanguageEnglish
Published England Royal Society of Chemistry 14.09.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Multidimensional peptide separations can greatly increase the depth of coverage in proteome profiling. However, a major challenge for multidimensional separations is the requirement of large biological samples, often containing milligram amounts of protein. We have developed nanowell-mediated two-dimensional (2D) reversed-phase nanoflow liquid chromatography (LC) separations for in-depth proteome profiling of low-nanogram samples. Peptides are first separated using high-pH LC and the effluent is concatenated into 4 or 12 nanowells. The contents of each nanowell are reconstituted in LC buffer and collected for subsequent separation and analysis by low-pH nanoLC-MS/MS. The nanowell platform minimizes peptide losses to surfaces in offline 2D LC fractionation, enabling >5800 proteins to be confidently identified from just 50 ng of HeLa digest. Furthermore, in combination with a recently developed nanowell-based sample preparation workflow, we demonstrated deep proteome profiling of >6000 protein groups from small populations of cells, including ∼650 HeLa cells and 10 single human pancreatic islet thin sections (∼1000 cells) from a pre-symptomatic type 1 diabetic donor.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
USDOE
DP3DK110844; UC4DK104167; R33CA225248; R21EB020976; AC05-76RL01830
PNNL-SA-133217
ISSN:2041-6520
2041-6539
DOI:10.1039/c8sc02680g